Skip to content
Evigrade
CriticalSelective irreversible MAO-B inhibitor×Antidepressant (other antidepressants, N06AX)

Updated · Methodology

Mechanism

Selegiline irreversibly inhibits monoamine oxidase type B (MAO-B). At the dose recommended for Parkinson's disease, 5–10 mg a day, it acts selectively, but above 10 mg it may lose its selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Platelet MAO-B activity returns to normal after about 2 weeks, because the body has to make new enzyme (selegiline SmPC, AEMPS). Vortioxetine inhibits the serotonin transporter and acts on serotonin receptors, and its risk of serotonin syndrome rises with drugs that affect serotonin metabolism, MAO inhibitors included (vortioxetine SmPC, European Medicines Agency, EMA). The EU vortioxetine SmPC expects a lower risk of serotonin syndrome with selective MAO-B inhibitors than with MAO-A inhibitors, but does not rule it out (vortioxetine SmPC, EMA). The elimination half-life of vortioxetine is 66 hours (vortioxetine SmPC, EMA).

Symptoms

Serotonin syndrome shows as changes in consciousness (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high body temperature), neuromuscular problems (overactive reflexes, poor coordination) and nausea, vomiting or diarrhoea, and it can be life-threatening (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). With monoamine oxidase inhibitors, vortioxetine also carries a higher risk of neuroleptic malignant syndrome (vortioxetine SmPC, EMA). The US vortioxetine label adds tremor, muscle rigidity, myoclonus and seizures (vortioxetine label, US Food and Drug Administration, FDA). After marketing, fatal and non-fatal cases of serotonin syndrome have been reported in people who took selegiline together with antidepressants (selegiline orally disintegrating tablets label, FDA).

Management

The combination is contraindicated under the US vortioxetine label: vortioxetine must not be taken with monoamine oxidase inhibitors (MAOIs), and the label names selegiline among the examples (vortioxetine label, US Food and Drug Administration, FDA). The EU vortioxetine summary of product characteristics (SmPC) is milder. It contraindicates non-selective MAOIs and selective MAO-A inhibitors, while irreversible MAO-B inhibitors, selegiline included, may be combined with vortioxetine with caution and closer monitoring for serotonin syndrome (vortioxetine SmPC, European Medicines Agency, EMA). In Spain, selegiline is authorised only for Parkinson's disease at 5–10 mg a day (selegiline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label of selegiline orally disintegrating tablets for Parkinson's disease advises avoiding its combination with any antidepressant (selegiline label, FDA). Start vortioxetine at least 14 days after stopping an MAOI, and start an MAOI at least 21 days after stopping vortioxetine (vortioxetine FDA label). If signs of serotonin syndrome appear, stop vortioxetine at once and start symptomatic treatment (vortioxetine SmPC, EMA). The US label adds stopping all other serotonergic drugs and supportive care (vortioxetine FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Selegiline

Other interactions with Vortioxetine